Mechanisms and Risk Factors of Cognitive Impairment in COPD

Topic Importance Cognitive impairment (CI) is an underrecognized extrapulmonary complication of COPD. Emerging evidence suggests that CI in COPD is both highly prevalent and clinically significant, with detrimental effects on disease management, medication adherence, exacerbation risk, and quality of life. The underlying biological mechanisms contributing to CI in COPD remain poorly defined. Review Findings Several plausible mechanisms have been implicated. For example, chronic hypoxemia has been associated with cerebral metabolic dysfunction and structural brain changes. Sleep-disordered breathing related to COPD can cause intermittent hypoxemia and sleep fragmentation, leading to glymphatic dysfunction, oxidative stress, and frontal lobe vulnerability. Oxidative stress, both systemic and cerebral, is exacerbated by smoking and inflammation, promoting endothelial dysfunction and DNA damage. Vascular dysfunction, including cerebral small-vessel disease and microbleeds, is associated with COPD and could be a co-occurrence because of shared risk factors, and correlates with cognitive decline. Finally, chronic hypercapnia contributes to CI through inflammatory, neurochemical, and cerebrovascular alterations, effects compounded when combined with hypoxemia. Summary Individuals with COPD that develop CI may reflect distinct biologically defined subtypes, rather than a uniform comorbidity. Current cognitive screening tools may underestimate CI in COPD, underscoring the need for validated, COPD-specific assessments. Although long-term oxygen therapy and treatment of sleep-disordered breathing show promise, their impact on cognition remains untested in trials with cognitive outcomes. Emerging tools (eg, multiomic profiling, tissue-based studies) may help identify high-risk subgroups and guide precision interventions. Given cost and eligibility constraints, precision risk stratification may improve feasibility of future trials.